Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology · Multiple Sclerosis

Planning for the Future: Prognosis and Your Care Team

At a Glance

Progressive MS follows a different course for each person, and no test can provide a precise personal timetable. Monitoring symptoms, MRI findings, walking and hand function, while working with a multidisciplinary care team, can help guide treatment and long-term planning.

Receiving a diagnosis of progressive MS can feel like being handed a map with an uncertain destination. However, modern research shows that the course of the disease is not a single, predictable clock. Instead, it is highly heterogeneous—meaning it varies significantly from one person to the next [1][2]. Understanding general risk factors and building a strong, multidisciplinary team are the most effective ways to take control of your health journey.

Understanding Your Personal Path

While every person is unique, researchers have identified several factors that may be associated with whether MS might progress more slowly or more quickly. This process is called risk stratification [2].

Factors Associated with a Faster Course

Certain findings at the time of diagnosis or during follow-up may suggest a faster-than-expected trajectory [2]. These are population-level associations, not a personal timetable:

  • Demographics: Older age at the start of symptoms and being male are often associated with a faster accumulation of disability [2][3].
  • Spinal Cord Involvement: Lesions or shrinkage (atrophy) in the spinal cord may be associated with physical disability, as the cord has less “room” for damage than the brain [4][5].
  • Brain Volume: Lower baseline brain volume or faster-than-average brain shrinkage can predict future worsening, even if you don’t have new lesions [6][7].
  • Chronic Activity: The presence of slowly expanding lesions or paramagnetic rim lesions (which show trapped, smoldering inflammation) is often a sign of more active progression [8][9].

The Role of PIRA

As discussed in the biology section, many people experience Progression Independent of Relapse Activity (PIRA). This describes confirmed clinical worsening that is not attributable to a relapse [10]. Recognizing PIRA early is crucial because it highlights that the disease is still progressing clinically, which can occur alongside or independently of MRI changes [8][6].

Long-Term Outlook: A New Era

In the past, the outlook for progressive MS was often framed by how long it would take to need a walking aid or wheelchair. Today, that timeline has been extended for many people due to better symptom management and newer disease-modifying therapies (DMTs) [11][12].

Long-term studies show that while some people experience rapid changes, many others follow a milder or moderate path for decades [13]. However, it is important to know that there is no reliable personal timetable.

Building Your Multidisciplinary Care Team

Because progressive MS affects many parts of the body and mind, a single doctor is rarely enough. A multidisciplinary team ensures that every symptom—from walking to mood to bladder function—is addressed [14][15].

  • Neurologist / Neuroimmunologist: The specialist of your team who manages your DMTs and monitors your scans [16].
  • Physiatrist (Rehabilitation Physician): A doctor who specializes in physical function, helping manage spasticity and mobility [17].
  • Physical (PT) and Occupational (OT) Therapists: Essential for maintaining strength, balance, and learning how to adapt your home or workspace [18][19].
  • Speech-Language Pathologist: Helps with swallowing difficulties or speech changes.
  • Urologist: A specialist to help with bladder and bowel symptoms, which are very common in progressive MS [20].
  • Neuropsychologist: Helps monitor and manage “brain fog” or changes in memory and processing speed [21].
  • Social Worker: Assists with navigating employment accommodations and accessing support resources.
  • Primary Care Physician: Crucial for managing comorbidities like high blood pressure or diabetes, which can actually make MS progression worse if left untreated [22][15].

Preparing for Your First Specialist Visit

When meeting an MS specialist for the first time, you are interviewing them as much as they are evaluating you. To make the most of your visit:

  1. Bring Your History: A list of every symptom, when it started, and if it was sudden or gradual.
  2. Bring Your Data: Have your MRI reports and, if possible, the actual images on a CD or digital drive.
  3. Define Your Goals: Tell your team what matters most to you—is it staying at work, being able to walk in the park, or improving your sleep?
  4. Ask About Monitoring: Ensure they plan to use more than just the EDSS score, including walking and hand-function tests, to track your progress [23][24].

Taking these steps transforms you from a passenger in your care to an active participant in your future. While the path of progressive MS may have its challenges, a proactive approach can significantly influence how you live your life [19][17].

Common questions in this guide

Can doctors predict exactly how progressive MS will affect me?
No single test can provide a precise personal timetable for progressive MS. The course varies widely, and factors such as age at symptom onset, spinal cord involvement, brain volume loss, and ongoing inflammatory activity may be associated with faster progression at the population level. These associations cannot determine exactly what will happen to one person.
What does PIRA mean in progressive MS?
PIRA stands for progression independent of relapse activity. It means confirmed worsening in function that is not explained by an MS relapse. PIRA can occur with or without new changes on an MRI, so clinical examinations and functional testing are important.
Which specialists may be part of a progressive MS care team?
A neurologist or neuroimmunologist usually coordinates MS treatment and monitoring. Depending on your needs, a physiatrist, physical or occupational therapist, speech-language pathologist, urologist, neuropsychologist, social worker, and primary care clinician may also help manage symptoms and daily life.
How is progression in MS monitored over time?
Monitoring may combine your symptom history, neurological examinations, MRI findings, and functional measures such as the EDSS, Timed 25-Foot Walk, and 9-Hole Peg Test. Establishing baseline walking and hand-function measurements makes it easier to identify meaningful change over time.
Can other health conditions affect progressive MS?
Yes. Conditions such as high blood pressure and diabetes may worsen MS progression when they are not well controlled. Regular primary care and coordinated management of these conditions can support overall health and MS care.
How should I prepare for my first visit with an MS specialist?
Bring a timeline of your symptoms, a current medication list, MRI reports, and the actual images if available. It also helps to identify your personal goals, such as staying at work, walking comfortably, or improving sleep, so the care team can tailor monitoring and support.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do you factor in my age and the duration of my disease when setting expectations for my long-term care?
  2. 2.Which specialists—such as a physiatrist, urologist, or speech therapist—should I see regularly to manage my symptoms and maintain my quality of life?
  3. 3.Can we use baseline tests like the Timed 25-Foot Walk and 9-Hole Peg Test now so we have a benchmark for the future?
  4. 4.How will my other health conditions, such as blood pressure or cholesterol, be managed to prevent them from worsening my MS?
  5. 5.Are there local support groups or resources for advance-care planning and employment accommodations that you recommend?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

    Signori A, Izquierdo G, Lugaresi A, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2018; (24(5)):642-652 doi:10.1177/1352458517703800.

    PMID: 28382837
  2. 2

    A data-driven model of disability progression in progressive multiple sclerosis.

    Garbarino S, Tur C, Lorenzi M, et al.

    Brain communications 2025; (7(1)):fcae434 doi:10.1093/braincomms/fcae434.

    PMID: 39777254
  3. 3

    Risk of secondary progressive multiple sclerosis: A longitudinal study.

    Fambiatos A, Jokubaitis V, Horakova D, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2020; (26(1)):79-90 doi:10.1177/1352458519868990.

    PMID: 31397221
  4. 4

    Preferential spinal cord volume loss in primary progressive multiple sclerosis.

    Tsagkas C, Magon S, Gaetano L, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2019; (25(7)):947-957 doi:10.1177/1352458518775006.

    PMID: 29781383
  5. 5

    Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.

    Bischof A, Papinutto N, Keshavan A, et al.

    Annals of neurology 2022; (91(2)):268-281 doi:10.1002/ana.26281.

    PMID: 34878197
  6. 6

    Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

    Miller DH, Lublin FD, Sormani MP, et al.

    Annals of clinical and translational neurology 2018; (5(3)):346-356 doi:10.1002/acn3.534.

    PMID: 29560379
  7. 7

    Deep gray matter volume loss drives disability worsening in multiple sclerosis.

    Eshaghi A, Prados F, Brownlee WJ, et al.

    Annals of neurology 2018; (83(2)):210-222 doi:10.1002/ana.25145.

    PMID: 29331092
  8. 8

    Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.

    Beynon V, George IC, Elliott C, et al.

    BMJ neurology open 2022; (4(1)):e000240 doi:10.1136/bmjno-2021-000240.

    PMID: 35720980
  9. 9

    Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression.

    Treaba CA, Conti A, Klawiter EC, et al.

    Brain communications 2021; (3(3)):fcab134 doi:10.1093/braincomms/fcab134.

    PMID: 34704024
  10. 10

    Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.

    Portaccio E, Bellinvia A, Fonderico M, et al.

    Brain : a journal of neurology 2022; (145(8)):2796-2805 doi:10.1093/brain/awac111.

    PMID: 35325059
  11. 11

    Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.

    Lizak N, Malpas CB, Sharmin S, et al.

    JAMA neurology 2020; (77(11)):1398-1407 doi:10.1001/jamaneurol.2020.2453.

    PMID: 32716480
  12. 12

    The window of opportunity for treatment of progressive multiple sclerosis.

    Sorensen PS, Fox RJ, Comi G

    Current opinion in neurology 2020; (33(3)):262-270 doi:10.1097/WCO.0000000000000811.

    PMID: 32251026
  13. 13

    Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.

    Signori A, Lorscheider J, Vukusic S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2023; (94(1)):23-30 doi:10.1136/jnnp-2022-329987.

    PMID: 36171104
  14. 14

    Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.

    Cristiano E, Rojas JI, Abad P, et al.

    Journal of the neurological sciences 2018; (393()):4-13 doi:10.1016/j.jns.2018.07.024.

    PMID: 30096568
  15. 15

    Progressive Multiple Sclerosis.

    Amezcua L

    Continuum (Minneapolis, Minn.) 2022; (28(4)):1083-1103 doi:10.1212/CON.0000000000001157.

    PMID: 35938658
  16. 16

    Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.

    Ziemssen T, Bhan V, Chataway J, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2023; (10(1)) doi:10.1212/NXI.0000000000200064.

    PMID: 36414428
  17. 17

    Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.

    Thompson AJ, Carroll W, Ciccarelli O, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2022; (28(1)):16-28 doi:10.1177/13524585211059766.

    PMID: 34850641
  18. 18

    Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study.

    Schreiber H, Penner IK, Maier T, et al.

    Journal of central nervous system disease 2024; (16()):11795735241296001 doi:10.1177/11795735241296001.

    PMID: 39449826
  19. 19

    Challenge of progressive multiple sclerosis therapy.

    Thompson AJ

    Current opinion in neurology 2017; (30(3)):237-240 doi:10.1097/WCO.0000000000000453.

    PMID: 28338498
  20. 20

    Progressive Multiple Sclerosis.

    Willis MA, Fox RJ

    Continuum (Minneapolis, Minn.) 2016; (22(3)):785-98 doi:10.1212/CON.0000000000000323.

    PMID: 27261682
  21. 21

    Cognitive function in primary and secondary progressive multiple sclerosis: A multiparametric magnetic resonance imaging study.

    Mistri D, Cacciaguerra L, Valsasina P, et al.

    European journal of neurology 2023; (30(9)):2801-2810 doi:10.1111/ene.15900.

    PMID: 37246467
  22. 22

    Comorbidity and Disease Activity in Multiple Sclerosis.

    Salter A, Lancia S, Kowalec K, et al.

    JAMA neurology 2024; doi:10.1001/jamaneurol.2024.2920.

    PMID: 39291661
  23. 23

    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

    Cadavid D, Cohen JA, Freedman MS, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(1)):94-105 doi:10.1177/1352458516638941.

    PMID: 27003945
  24. 24

    Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.

    Koch MW, Mostert J, Repovic P, et al.

    Neurology 2021; (96(1)):e111-e120 doi:10.1212/WNL.0000000000011123.

    PMID: 33106389

This page about progressive MS prognosis and care planning is for informational purposes only and does not constitute medical advice. Your neurologist and care team can interpret your individual risk factors and recommend appropriate monitoring and support.

Get notified when new evidence is published on progressive relapsing multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.